Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive…
JACKSONVILLE, Fla.--(BUSINESS WIRE)--To help ensure more families have access to educational resources they need for healthy birth outcomes, the Northeast…
JACKSONVILLE, Fla.--(BUSINESS WIRE)--To help ensure more families have access to educational resources they need for healthy birth outcomes, the Northeast…
Combining Advanced Remote Patient Monitoring Technology with Comprehensive Virtual Maternity Services AUSTIN, Texas and ST. PAUL, Minn., Dec. 6, 2024…
DARIEN, Conn., Dec. 3, 2024 /PRNewswire/ -- Medical device maker CEFALY Technology today launched the CEFALY Pregnancy Registry, a new…
The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable…
The world-first tailored care plans address over 40 conditions, including Polycystic Ovary Syndrome (PCOS), Endometriosis, Gestational Diabetes, Preeclampsia, and more.…
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patientsATLANTA, Nov.…
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been…